Subscribe
jhve-1
JHVEPhoto / Shutterstock.com
26 August 2020AmericasRory O'Neill

Intercept sues Apotex over Ocaliva generic

Intercept Pharmaceuticals is suing Canadian generics manufacturer  Apotex over a proposed version of autoimmune drug  Ocaliva (obeticholic acid).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Takeda, Bayer settle $173m Adynovate suit
20 May 2021   Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Americas
Orexo sues Sun Pharma over opioid dependence generic
16 September 2020   Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Big Pharma
Bayer, Apotex settle suit over cancer drug patent
13 August 2020   Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Americas
Takeda, Bayer settle $173m Adynovate suit
20 May 2021   Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Americas
Orexo sues Sun Pharma over opioid dependence generic
16 September 2020   Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Big Pharma
Bayer, Apotex settle suit over cancer drug patent
13 August 2020   Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.

More on this story

Americas
Takeda, Bayer settle $173m Adynovate suit
20 May 2021   Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Americas
Orexo sues Sun Pharma over opioid dependence generic
16 September 2020   Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Big Pharma
Bayer, Apotex settle suit over cancer drug patent
13 August 2020   Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
The rise of pro-NPE and patent sentiment in the US